Vertex Achieves Gene-Editing Milestone With First Ever CRISPR Therapy Approval

Great Britain is first to approve the groundbreaking CRISPR-based therapy for sickle cell and beta thalassemia. Vertex is yet to reveal its price, however, and wants to play down early expectations of its commercial potential.